Press Releases

Date Title and Summary    
Toggle Summary Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on March 16 Oppenheimer 28th Annual Healthcare Conference on March 21 ROCKVILLE, Md., March 13, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results
ROCKVILLE, Md., March 12, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the year ended December 31, 2017.
View HTML Print
Toggle Summary Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Advanced Bladder Cancer Who Had Failed on Multiple Prior Treatments Including Immunotherapy and Gemcitabine
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma
Haichang to fund development through completion of Phase IIa Proof-of-Concept Clinical Trial Clinical trials will be designed to meet both the US and China FDA requirements ROCKVILLE, Md., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc.
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
ROCKVILLE, Md., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will present preliminary clinical data from the Phase 2a
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
Patent Protection for RX-5902 (Supinoxin™) Extended until 2036 for Multiple Cancers including Triple Negative Breast Cancer
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Metastatic Pancreatic Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments Rexahn is Progressing Development of RX-3117 in Combination with Abraxane® in Newly Diagnosed Pancreatic
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
ROCKVILLE, Md., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will present clinical data from the completed Phase IIa
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018
ROCKVILLE, Md., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that Peter D. Suzdak, Ph.D., the Company's Chief Executive Officer,
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer
ROCKVILLE, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced the appointment of Douglas J.
View HTML Print


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy